These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36698747)

  • 1. Polycystic Kidney Disease Drug Development: A Conference Report.
    Liebau MC; Mekahli D; Perrone R; Soyfer B; Fedeles S
    Kidney Med; 2023 Mar; 5(3):100596. PubMed ID: 36698747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
    Smith KA; Thompson AM; Baron DA; Broadbent ST; Lundstrom GH; Perrone RD
    Am J Kidney Dis; 2019 Apr; 73(4):533-541. PubMed ID: 30600104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
    Perrone RD; Neville J; Chapman AB; Gitomer BY; Miskulin DC; Torres VE; Czerwiec FS; Dennis E; Kisler B; Kopko S; Krasa HB; LeRoy E; Castedo J; Schrier RW; Broadbent S
    Am J Kidney Dis; 2015 Oct; 66(4):583-90. PubMed ID: 26088508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China.
    Xue C; Zhou CC; Wu M; Mei CL
    Kidney Dis (Basel); 2016 Oct; 2(3):111-119. PubMed ID: 27921038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered Registry.
    Hoover E; Holliday V; Merullo N; Oberdhan D; Perrone RD; Rusconi C; Park M; Phadnis MA; Thewarapperuma N; Dahl NK
    Kidney Med; 2024 May; 6(5):100813. PubMed ID: 38689835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
    Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
    Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease.
    Cho Y; Sautenet B; Rangan G; Craig JC; Ong ACM; Chapman A; Ahn C; Chen D; Coolican H; Kao JT; Gansevoort R; Perrone R; Harris T; Torres V; Pei Y; Kerr PG; Ryan J; Gutman T; Howell M; Ju A; Manera KE; Teixeira-Pinto A; Hamiwka LA; Tong A
    Trials; 2017 Nov; 18(1):560. PubMed ID: 29169385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Development in Autosomal Dominant Polycystic Kidney Disease: Opportunities and Challenges.
    Chebib FT; Perrone RD
    Adv Kidney Dis Health; 2023 May; 30(3):261-284. PubMed ID: 37088528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.
    Olalekan K; Fox A; Gilbert R
    Arch Dis Child; 2016 Sep; 101(9):e2. PubMed ID: 27540244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
    Chebib FT; Torres VE
    Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop.
    Cho Y; Tong A; Craig JC; Mustafa RA; Chapman A; Perrone RD; Ahn C; Fowler K; Torres V; Gansevoort RT; Ong ACM; Coolican H; Tze-Wah Kao J; Harris T; Gutman T; Shen JI; Viecelli AK; Johnson DW; Au E; El-Damanawi R; Logeman C; Ju A; Manera KE; Chonchol M; Odland D; Baron D; Pei Y; Sautenet B; Rastogi A; Sharma A; Rangan G;
    Am J Kidney Dis; 2021 Feb; 77(2):255-263. PubMed ID: 32771648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease.
    Liebau MC; Serra AL
    Pediatr Nephrol; 2013 Sep; 28(9):1771-83. PubMed ID: 23239392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?
    Liu F; Feng C; Shen H; Fu H; Mao J
    Kidney Dis (Basel); 2021 Sep; 7(5):343-349. PubMed ID: 34604341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tolvaptan, a vasopressin V
    Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y
    Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options.
    Radhakrishnan Y; Duriseti P; Chebib FT
    Kidney Res Clin Pract; 2022 Jul; 41(4):422-431. PubMed ID: 35354242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Congenital hepatic fibrosis and portal hypertension in autosomal dominant polycystic kidney disease.
    O'Brien K; Font-Montgomery E; Lukose L; Bryant J; Piwnica-Worms K; Edwards H; Riney L; Garcia A; Daryanani K; Choyke P; Mohan P; Heller T; Gahl WA; Gunay-Aygun M
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):83-9. PubMed ID: 21694639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus.
    Soroka S; Alam A; Bevilacqua M; Girard LP; Komenda P; Loertscher R; McFarlane P; Pandeya S; Tam P; Bichet DG
    Can J Kidney Health Dis; 2017; 4():2054358117695784. PubMed ID: 28321325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.